Reducing workforce by 85 employees and taking a one-time charge of approximately $10 mil. in its third quarter, as part of a restructuring announced Oct. 29. "Due to the delays we have encountered with E5 and CD5 Plus, we are refocusing and streamlining our organization," CEO Jack Castello explained. Xoma will "emphasize" the development of human bactericidal/permeability increasing (BPI) protein-based products for infections and T-cell targeted products for autoimmune disease, while continuing the clinical development of E5 for gram- negative sepsis and CD5 Plus solely for graft-versus-host-disease.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth